Company Filing History:
Years Active: 2010-2011
Title: Innovations of Linda O'Bryan: Pioneering Anti-Myostatin Antibodies in Indianapolis
Introduction
Linda O'Bryan, formerly known as Linda Tobias, is an innovative inventor based in Indianapolis, Indiana. With a remarkable contribution to the field of biotechnology, she holds two patents that focus on the development of anti-myostatin antibodies. Her work has profound implications for increasing muscle mass and treating various disorders in mammalian and avian species.
Latest Patents
Linda's latest patents revolve around the discovery of anti-myostatin antibodies characterized by their high affinity. These antibodies may be chimeric, humanized, or fully human, and can be utilized in the form of immunoconjugates or antigen-binding fragments. The specifics of her first patent, designated X17251, highlight the antibodies as being instrumental in increasing muscle mass and bone density, making significant strides in therapeutic options for several disorders.
Another key patent addresses the identification of a neutralizing epitope within amino acids 40-64 of the mature form of human myostatin. Antibodies binding this epitope exhibit a preference for GDF-8 over GDF-11, signaling a refined approach to targeting specific biological pathways. Both patents are pivotal in advancing healthcare solutions related to muscle growth and metabolic disorders.
Career Highlights
Linda O'Bryan currently works at Eli Lilly and Company, where her research and inventions have flourished. Her contributions are essential in positioning the company at the forefront of biotechnological advancements. Linda's commitment to innovation is evident through her meticulous research and dedication to developing new treatments.
Collaborations
Throughout her career, Linda has collaborated with notable coworkers, including Andrew Ihor Korytko and Pamela Jean Mitchell. These partnerships have facilitated a productive environment for shared ideas and innovations that push the boundaries in the field of biotechnology.
Conclusion
Linda O'Bryan's contributions to the field of anti-myostatin antibodies highlight her role as a significant inventor with a lasting impact on healthcare. Based in Indianapolis, her innovative spirit and collaborative efforts exemplify the potential of biotechnology to revolutionize treatment approaches for muscle and bone disorders. As she continues her work at Eli Lilly and Company, the future holds promising advancements that could emerge from her ongoing research and innovations.